ctDNA Improved Predictor of Survival for Previously Treated Metastatic Uveal Melanoma
Source: cancernetwork, September 2021
For patients with previously treated, HLA-A*02:01-positive metastatic uveal melanoma (mUM) assigned to tebentafusp (IMCgp100), circulating tumor DNA (ctDNA) was an improved predictor of survival compared to RECIST 1.1, according to findings presented at the 2021 European Society for Medical Oncology Congress.1
